Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
MYOS's Cash-to-Debt is ranked higher than
93% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MYOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MYOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.94
MYOS's Equity-to-Asset is ranked higher than
96% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYOS: 0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
MYOS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17  Med: 0.87 Max: 0.96
Current: 0.94
0.17
0.96
Piotroski F-Score: 4
Altman Z-Score: 4.94
Beneish M-Score: -9.77
WACC vs ROIC
12.10%
-110.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1395.64
MYOS's Operating Margin % is ranked lower than
95% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. MYOS: -1395.64 )
Ranked among companies with meaningful Operating Margin % only.
MYOS' s Operating Margin % Range Over the Past 10 Years
Min: -4642.42  Med: -824.96 Max: -128.6
Current: -1395.64
-4642.42
-128.6
Net Margin % -1396.73
MYOS's Net Margin % is ranked lower than
95% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. MYOS: -1396.73 )
Ranked among companies with meaningful Net Margin % only.
MYOS' s Net Margin % Range Over the Past 10 Years
Min: -5653.54  Med: -878.35 Max: -128.48
Current: -1396.73
-5653.54
-128.48
ROE % -68.45
MYOS's ROE % is ranked lower than
89% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. MYOS: -68.45 )
Ranked among companies with meaningful ROE % only.
MYOS' s ROE % Range Over the Past 10 Years
Min: -2665.24  Med: -110.45 Max: -68.45
Current: -68.45
-2665.24
-68.45
ROA % -59.53
MYOS's ROA % is ranked lower than
92% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. MYOS: -59.53 )
Ranked among companies with meaningful ROA % only.
MYOS' s ROA % Range Over the Past 10 Years
Min: -2600  Med: -79.64 Max: -45
Current: -59.53
-2600
-45
ROC (Joel Greenblatt) % -223.47
MYOS's ROC (Joel Greenblatt) % is ranked lower than
86% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. MYOS: -223.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -371466.67  Med: -504.69 Max: -205.82
Current: -223.47
-371466.67
-205.82
3-Year Revenue Growth Rate -64.30
MYOS's 3-Year Revenue Growth Rate is ranked lower than
98% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MYOS: -64.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 144.7
Current: -64.3
0
144.7
3-Year EBITDA Growth Rate -23.90
MYOS's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. MYOS: -23.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41  Med: -3.6 Max: 530.5
Current: -23.9
-41
530.5
3-Year EPS without NRI Growth Rate -22.50
MYOS's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MYOS: -22.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -29.8 Max: 400
Current: -22.5
0
400
GuruFocus has detected 1 Warning Sign with Myos Rens Technology Inc $MYOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYOS's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:PTLF, TSX:EPI, BOM:524689, XCNQ:DOJA, OTCPK:ULUR, BSE:RMAH, OTCPK:PVCT, BOM:532878, BOM:530477, OTCPK:ACUR, XLIS:CPN, BOM:539997, BOM:538964, BOM:531739, TSXV:AQS, XSAT:DBP B, ASX:ESE, AMEX:IGC, TSXV:LBL, NSE:PARABDRUGS » details
Traded in other countries:73M.Germany,
Headquarter Location:USA
Myos Rens Technology Inc is engaged in discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health.

Myos Rens Technology Inc is engaged in discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health.

Ratios

vs
industry
vs
history
PB Ratio 1.53
MYOS's PB Ratio is ranked higher than
74% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. MYOS: 1.53 )
Ranked among companies with meaningful PB Ratio only.
MYOS' s PB Ratio Range Over the Past 10 Years
Min: 0.93  Med: 3.28 Max: 16.26
Current: 1.53
0.93
16.26
PS Ratio 26.80
MYOS's PS Ratio is ranked lower than
90% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. MYOS: 26.80 )
Ranked among companies with meaningful PS Ratio only.
MYOS' s PS Ratio Range Over the Past 10 Years
Min: 4.15  Med: 21.29 Max: 465.12
Current: 26.8
4.15
465.12
EV-to-EBIT -1.75
MYOS's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. MYOS: -1.75 )
Ranked among companies with meaningful EV-to-EBIT only.
MYOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.2  Med: -3.1 Max: -0.3
Current: -1.75
-30.2
-0.3
EV-to-EBITDA -1.90
MYOS's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. MYOS: -1.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.5  Med: -3.15 Max: -0.4
Current: -1.9
-30.5
-0.4
EV-to-Revenue 24.32
MYOS's EV-to-Revenue is ranked lower than
89% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. MYOS: 24.32 )
Ranked among companies with meaningful EV-to-Revenue only.
MYOS' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.2  Med: 18.5 Max: 467.3
Current: 24.32
4.2
467.3
Current Ratio 9.95
MYOS's Current Ratio is ranked higher than
91% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. MYOS: 9.95 )
Ranked among companies with meaningful Current Ratio only.
MYOS' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 4.3 Max: 27.24
Current: 9.95
0.03
27.24
Quick Ratio 4.39
MYOS's Quick Ratio is ranked higher than
77% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. MYOS: 4.39 )
Ranked among companies with meaningful Quick Ratio only.
MYOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3 Max: 26.31
Current: 4.39
0.03
26.31
Days Inventory 2.00
MYOS's Days Inventory is ranked higher than
98% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. MYOS: 2.00 )
Ranked among companies with meaningful Days Inventory only.
MYOS' s Days Inventory Range Over the Past 10 Years
Min: 2  Med: 509.6 Max: 1919.9
Current: 2
2
1919.9
Days Sales Outstanding 10.62
MYOS's Days Sales Outstanding is ranked higher than
94% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. MYOS: 10.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.93  Med: 75.9 Max: 932.01
Current: 10.62
8.93
932.01
Days Payable 54.13
MYOS's Days Payable is ranked lower than
63% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. MYOS: 54.13 )
Ranked among companies with meaningful Days Payable only.
MYOS' s Days Payable Range Over the Past 10 Years
Min: 20.31  Med: 98.83 Max: 258.59
Current: 54.13
20.31
258.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.80
MYOS's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. MYOS: -33.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33.8  Med: -30.9 Max: -8.4
Current: -33.8
-33.8
-8.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.57
MYOS's Price-to-Net-Cash is ranked higher than
54% of the 234 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.00 vs. MYOS: 9.57 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MYOS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.28  Med: 7.52 Max: 34.02
Current: 9.57
2.28
34.02
Price-to-Net-Current-Asset-Value 2.63
MYOS's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. MYOS: 2.63 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MYOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.55  Med: 4.83 Max: 80.17
Current: 2.63
1.55
80.17
Price-to-Tangible-Book 2.35
MYOS's Price-to-Tangible-Book is ranked higher than
65% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. MYOS: 2.35 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MYOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.48  Med: 4.51 Max: 81.01
Current: 2.35
1.48
81.01
Price-to-Median-PS-Value 1.26
MYOS's Price-to-Median-PS-Value is ranked lower than
69% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. MYOS: 1.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.02 Max: 17.58
Current: 1.26
0.24
17.58
Earnings Yield (Greenblatt) % -57.16
MYOS's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. MYOS: -57.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -297.3  Med: -32.3 Max: -3.3
Current: -57.16
-297.3
-3.3

More Statistics

Revenue (TTM) (Mil) $0.28
EPS (TTM) $ -0.70
Beta1.64
Short Percentage of Float11.27%
52-Week Range $1.02 - 6.98
Shares Outstanding (Mil)5.84

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}